CL2014001016A1 - Compuestos triciclicos condensados y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende; y su uso en el tratamiento de una infeccion viral. - Google Patents
Compuestos triciclicos condensados y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende; y su uso en el tratamiento de una infeccion viral.Info
- Publication number
- CL2014001016A1 CL2014001016A1 CL2014001016A CL2014001016A CL2014001016A1 CL 2014001016 A1 CL2014001016 A1 CL 2014001016A1 CL 2014001016 A CL2014001016 A CL 2014001016A CL 2014001016 A CL2014001016 A CL 2014001016A CL 2014001016 A1 CL2014001016 A1 CL 2014001016A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salts
- viral infection
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549784P | 2011-10-21 | 2011-10-21 | |
| US201261692431P | 2012-08-23 | 2012-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014001016A1 true CL2014001016A1 (es) | 2015-01-16 |
Family
ID=48141628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001016A CL2014001016A1 (es) | 2011-10-21 | 2014-04-21 | Compuestos triciclicos condensados y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende; y su uso en el tratamiento de una infeccion viral. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20140249143A1 (es) |
| EP (1) | EP2768506A4 (es) |
| JP (1) | JP2014532626A (es) |
| KR (1) | KR20140094559A (es) |
| CN (1) | CN103957910A (es) |
| AR (1) | AR088793A1 (es) |
| AU (1) | AU2012325971B2 (es) |
| BR (1) | BR112014008727A2 (es) |
| CA (1) | CA2851801A1 (es) |
| CL (1) | CL2014001016A1 (es) |
| CO (1) | CO6910198A2 (es) |
| CR (1) | CR20140175A (es) |
| DO (1) | DOP2014000081A (es) |
| EA (1) | EA201490610A1 (es) |
| IL (1) | IL231894A0 (es) |
| MX (1) | MX2014004814A (es) |
| PE (1) | PE20141359A1 (es) |
| PH (1) | PH12014500865A1 (es) |
| SG (2) | SG11201400988SA (es) |
| TW (2) | TW201333003A (es) |
| UY (1) | UY34406A (es) |
| WO (1) | WO2013059559A2 (es) |
| ZA (1) | ZA201402392B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103333168B (zh) * | 2013-07-23 | 2015-08-05 | 清华大学 | 一种酰胺类化合物及其制备方法与应用 |
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| EP3200778A4 (en) | 2014-09-29 | 2018-05-23 | The Trustees Of The University Of Pennsylvania | Antivirals against molluscum contagiosum virus |
| CN104529893B (zh) * | 2014-12-30 | 2016-08-24 | 中国科学技术大学 | 一类可以作为高尔基体细胞器探针的喹啉染料 |
| CN105175277B (zh) * | 2015-05-18 | 2018-04-03 | 中山大学肿瘤防治中心 | 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用 |
| WO2018043747A1 (ja) * | 2016-09-05 | 2018-03-08 | 国立大学法人京都大学 | 抗ｂ型肝炎ウイルス剤 |
| US11912706B2 (en) | 2017-03-28 | 2024-02-27 | Pimera, Inc. | Crystal forms of a POL1 inhibitor |
| JP7443357B2 (ja) | 2018-10-23 | 2024-03-05 | ビーエーエスエフ ソシエタス・ヨーロピア | 三環式の殺有害生物化合物 |
| CN114732822B (zh) * | 2019-03-13 | 2023-06-30 | 中国人民解放军军事科学院军事医学研究院 | 氨基葡萄糖及其衍生物作为抗病毒药物的应用 |
| AU2021256876A1 (en) | 2020-04-14 | 2022-11-03 | Basf Se | Tricyclic pesticidal compounds |
| JP2023539896A (ja) * | 2020-09-03 | 2023-09-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｓａｒｓ－ｃｏｖ－２感染を治療するためのｉｆｎａｒ２アゴニストとしてのイミダゾナフチリジンおよびイミダゾピリドピリミジン |
| WO2022175425A1 (en) | 2021-02-22 | 2022-08-25 | Glaxosmithkline Intellectual Property Development Limited | Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| EP4408536A1 (en) | 2021-10-01 | 2024-08-07 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| KR20240101561A (ko) | 2021-10-14 | 2024-07-02 | 인사이트 코포레이션 | Kras의 저해제로서의 퀴놀린 화합물 |
| WO2023244672A1 (en) | 2022-06-14 | 2023-12-21 | Assembly Biosciences, Inc. | 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections |
| US20240400554A1 (en) * | 2023-04-14 | 2024-12-05 | HUMANWELL PHARMACEUTICAL US, Inc. | Monoacylglycerol lipase (magl) inhibitors for the treatment of pain and related medical disorders |
| WO2025089372A1 (ja) * | 2023-10-26 | 2025-05-01 | 国立研究開発法人理化学研究所 | イソインドリン誘導体 |
| WO2025128898A1 (en) | 2023-12-13 | 2025-06-19 | Assembly Biosciences, Inc. | Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections |
| WO2026084958A1 (en) | 2024-10-14 | 2026-04-23 | Assembly Biosciences, Inc. | Tricyclic heteroaryl compounds useful for enhancing innate immune responses |
| WO2026084957A1 (en) | 2024-10-14 | 2026-04-23 | Assembly Biosciences, Inc. | Tricyclic heteroaryl compounds useful for enhancing innate immune responses |
| WO2026084955A1 (en) | 2024-10-14 | 2026-04-23 | Assembly Biosciences, Inc. | Tricyclic heteroaryl compounds useful for enhancing innate immune responses |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE441449B (sv) * | 1979-02-09 | 1985-10-07 | Roussel Uclaf | Heterocykliska derivat och farmaceutiska kompositioner innehallande dessa derivat |
| US4492697A (en) * | 1983-08-16 | 1985-01-08 | Ayerst, Mckenna & Harrison, Inc. | 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives |
| US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| PL374544A1 (en) * | 2002-04-03 | 2005-10-31 | F.Hoffmann-La Roche Ag | Imidazo fused compounds |
| US8592368B2 (en) * | 2003-12-19 | 2013-11-26 | University Of South Florida | JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection |
| DE102005019181A1 (de) * | 2005-04-25 | 2006-10-26 | Novartis Ag | Peptid-Deformylase (PDF) Inhibitoren 1 |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| EP2416488B1 (en) * | 2009-03-31 | 2019-03-06 | Daikin Industries, Ltd. | Electrode film for polymer actuator element, and polymer actuator element comprising same |
| GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB201002409D0 (en) * | 2010-02-12 | 2010-03-31 | Univ Nottingham | Methods |
-
2012
- 2012-10-19 SG SG11201400988SA patent/SG11201400988SA/en unknown
- 2012-10-19 CN CN201280051347.8A patent/CN103957910A/zh active Pending
- 2012-10-19 JP JP2014537274A patent/JP2014532626A/ja active Pending
- 2012-10-19 AU AU2012325971A patent/AU2012325971B2/en not_active Ceased
- 2012-10-19 WO PCT/US2012/060971 patent/WO2013059559A2/en not_active Ceased
- 2012-10-19 KR KR1020147013668A patent/KR20140094559A/ko not_active Withdrawn
- 2012-10-19 BR BR112014008727A patent/BR112014008727A2/pt not_active IP Right Cessation
- 2012-10-19 PE PE2014000559A patent/PE20141359A1/es not_active Application Discontinuation
- 2012-10-19 PH PH1/2014/500865A patent/PH12014500865A1/en unknown
- 2012-10-19 SG SG10201505664WA patent/SG10201505664WA/en unknown
- 2012-10-19 US US14/353,067 patent/US20140249143A1/en not_active Abandoned
- 2012-10-19 CA CA2851801A patent/CA2851801A1/en not_active Abandoned
- 2012-10-19 MX MX2014004814A patent/MX2014004814A/es unknown
- 2012-10-19 EP EP12840986.9A patent/EP2768506A4/en not_active Withdrawn
- 2012-10-19 EA EA201490610A patent/EA201490610A1/ru unknown
- 2012-10-22 TW TW101138997A patent/TW201333003A/zh unknown
- 2012-10-22 UY UY0001034406A patent/UY34406A/es not_active Application Discontinuation
- 2012-10-22 AR ARP120103945A patent/AR088793A1/es unknown
- 2012-10-22 TW TW104126180A patent/TW201542567A/zh unknown
-
2014
- 2014-03-18 CO CO14058151A patent/CO6910198A2/es unknown
- 2014-03-31 ZA ZA2014/02392A patent/ZA201402392B/en unknown
- 2014-04-03 IL IL231894A patent/IL231894A0/en unknown
- 2014-04-21 CL CL2014001016A patent/CL2014001016A1/es unknown
- 2014-04-21 DO DO2014000081A patent/DOP2014000081A/es unknown
- 2014-04-21 CR CR20140175A patent/CR20140175A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013059559A2 (en) | 2013-04-25 |
| EP2768506A4 (en) | 2015-08-19 |
| US20140249143A1 (en) | 2014-09-04 |
| SG11201400988SA (en) | 2014-07-30 |
| KR20140094559A (ko) | 2014-07-30 |
| TW201542567A (zh) | 2015-11-16 |
| AU2012325971A1 (en) | 2014-04-17 |
| MX2014004814A (es) | 2014-05-27 |
| CA2851801A1 (en) | 2013-04-25 |
| JP2014532626A (ja) | 2014-12-08 |
| SG10201505664WA (en) | 2015-09-29 |
| AU2012325971B2 (en) | 2016-03-31 |
| CO6910198A2 (es) | 2014-03-31 |
| UY34406A (es) | 2013-05-31 |
| DOP2014000081A (es) | 2014-07-15 |
| AR088793A1 (es) | 2014-07-10 |
| WO2013059559A3 (en) | 2013-11-14 |
| ZA201402392B (en) | 2017-09-27 |
| TW201333003A (zh) | 2013-08-16 |
| IL231894A0 (en) | 2014-05-28 |
| CR20140175A (es) | 2014-06-03 |
| EP2768506A2 (en) | 2014-08-27 |
| EA201490610A1 (ru) | 2014-09-30 |
| CN103957910A (zh) | 2014-07-30 |
| BR112014008727A2 (pt) | 2017-04-25 |
| PE20141359A1 (es) | 2014-10-13 |
| PH12014500865A1 (en) | 2014-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014001585A1 (es) | Compuestos derivados de betulina; composicion farmaceutica; y el uso de los mismos en el tratamiento y prevencion de una infeccion por vih. | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2013003019A1 (es) | Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih. | |
| CL2015001756A1 (es) | Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion. | |
| CL2014000732A1 (es) | Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende. | |
| CL2013003229A1 (es) | Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc. | |
| CL2015001702A1 (es) | Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c. | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| GT201400009A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk | |
| CL2014000370A1 (es) | Hemifumarato de tenofovir alafenamida; metodo de preparación; composicion farmaceutica que lo comprende; metodo para preparar la composicion farmaceutica; y uso en el tratamiento de una infeccion por hiv. | |
| CL2015000345A1 (es) | Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib. | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CL2014002392A1 (es) | Uso de nucleosidos, nucleotidos sustituidos y análogos de los mismos para el tratamiento de una infeccion viral. | |
| DOP2014000081A (es) | Compuestos y procedimientos para mejorar las respuestas inmunitarias innatas | |
| CL2012000573A1 (es) | Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv. | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| UY33775A (es) | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos | |
| ECSP15000435A (es) | Inhibidores macrocíclicos de virus flaviviridae | |
| ECSP15007322A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2015001916A1 (es) | Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral. | |
| CO6900149A2 (es) | Una composición farmacéutica que comprende los fitocanabinoides canabidivarina (cbdv) y canabidiol (cbd) | |
| CL2014001399A1 (es) | Compuestos de reversion anticoagulante; composicion farmaceutica y el uso de los mismos para revertir el efecto anticoagulante de un inhibidor de la coagulacion. | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| CO7240410A2 (es) | Inhibidores macrocíclicos de virus flaviviridae |